Johnson & Johnson and Pfizer pinch each other. Why is the effect of Johnson & Johnson medical products always questioned?

After all, Johnson & Johnson brand has more people and higher attention. Moreover, what Johnson & Johnson does is mainly used on people, so it is also concerned. If there are any harmful substances, what dangers will it bring to people. Nowadays, people pay more attention to health and safety. Moreover, Johnson & Johnson has also seen many examples of casualties, which has to be paid more attention to.

Pfizer and Johnson & Johnson, one in new york and the other in New Jersey, are both local pharmaceutical companies in the United States, and there is no lack of struggle in the American market. Pfizer filed a lawsuit against Johnson & Johnson, accusing the latter of obstructing the use of competitive biosimilar products of Remicade, an arthritis treatment drug, and preventing medical insurance companies, hospitals and clinics from providing cheaper biosimilar products in Pfizer.

Remicade is the best-selling anti-inflammatory drug in the world, mainly treating chronic diseases such as rheumatoid arthritis, plaque psoriasis and Crohn's disease. The global sales in 20 14 reached 9.24 billion dollars, ranking third in the top 25 drugs in global sales in 20 14.

Pfizer filed a lawsuit in the federal court in Philadelphia. According to the lawsuit, Johnson & Johnson's exclusive contract forced hospitals and clinics to stop buying Inflectira, a biosimilar drug from Pfizer, and medical insurance companies stopped paying prescriptions involving Inflectira to get kickbacks and other benefits. Pfizer asked the above-mentioned federal district court to declare such contracts invalid and demanded that Johnson & Johnson compensate for the loss of sales.

The two companies are in a competitive state and both want to kill each other, so it is normal for the two companies to pinch each other. If one side wins, the benefits they get are immeasurable.